Universal Forest Products, Inc. (UFPI) Forms $37.30 Double Top; Healthcor Management LP Has Decreased By $80.86 Million Its Sarepta Therapeutics (Call) (SRPT) Stake

Universal Forest Products, Inc. (UFPI) formed double top with $40.28 target or 8.00% above today’s $37.30 share price. Universal Forest Products, Inc. (UFPI) has $2.28B valuation. The stock decreased 0.40% or $0.15 during the last trading session, reaching $37.3. About 12,431 shares traded. Universal Forest Products, Inc. (NASDAQ:UFPI) has risen 12.86% since January 17, 2017 and is uptrending. It has underperformed by 3.84% the S&P500.

Healthcor Management Lp decreased Sarepta Therapeutics Inc (Call) (SRPT) stake by 88.43% reported in 2017Q3 SEC filing. Healthcor Management Lp sold 1.80 million shares as Sarepta Therapeutics Inc (Call) (SRPT)’s stock rose 22.49%. The Healthcor Management Lp holds 235,000 shares with $10.66M value, down from 2.03M last quarter. Sarepta Therapeutics Inc (Call) now has $3.91 billion valuation. The stock increased 0.55% or $0.33 during the last trading session, reaching $60.48. About 102,299 shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 96.82% since January 17, 2017 and is uptrending. It has outperformed by 80.12% the S&P500.

Healthcor Management Lp increased Boston Scientific Corp (NYSE:BSX) stake by 233,220 shares to 687,170 valued at $20.05M in 2017Q3. It also upped Livanova Plc stake by 531,530 shares and now owns 931,530 shares. Allergan Plc was raised too.

Analysts await Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to report earnings on February, 27. They expect $-0.35 EPS, up 77.85% or $1.23 from last year’s $-1.58 per share. After $-0.78 actual EPS reported by Sarepta Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -55.13% EPS growth.

Since October 3, 2017, it had 0 buys, and 1 sale for $575,000 activity. The insider Ruff Shamim sold $575,000.

Among 27 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 21 have Buy rating, 0 Sell and 6 Hold. Therefore 78% are positive. Sarepta Therapeutics had 95 analyst reports since August 5, 2015 according to SRatingsIntel. On Tuesday, April 26 the stock rating was downgraded by SunTrust to “Reduce”. As per Wednesday, August 26, the company rating was maintained by TH Capital. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) earned “Hold” rating by Jefferies on Monday, September 19. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) earned “Equal-Weight” rating by Barclays Capital on Thursday, October 26. Credit Suisse initiated it with “Outperform” rating and $68 target in Tuesday, October 18 report. Needham maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Thursday, October 26 with “Buy” rating. On Wednesday, April 20 the stock rating was initiated by Janney Capital with “Neutral”. The firm has “Neutral” rating by Wedbush given on Thursday, April 21. The firm has “Hold” rating given on Wednesday, September 6 by Barclays Capital. The firm has “Buy” rating by SunTrust given on Wednesday, April 5.

Investors sentiment increased to 2.88 in 2017 Q3. Its up 1.36, from 1.52 in 2017Q2. It improved, as 24 investors sold SRPT shares while 27 reduced holdings. 63 funds opened positions while 84 raised stakes. 51.70 million shares or 25.22% more from 41.29 million shares in 2017Q2 were reported. Eventide Asset Mngmt stated it has 161,000 shares. Elk Creek reported 716,516 shares. Commonwealth Equity Svcs Inc holds 0% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 7,714 shares. Jane Street Grp Ltd Liability Corporation invested in 0.01% or 67,194 shares. Dupont Cap reported 12,722 shares stake. Ghost Tree Cap accumulated 100,000 shares. Bankshares Of Montreal Can holds 0% or 84,604 shares in its portfolio. Raymond James & invested 0% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Parkside Retail Bank Trust holds 0% or 85 shares in its portfolio. First Tru Advisors LP has 57,668 shares. Pictet Asset Mgmt Limited reported 36,400 shares. New York-based Amalgamated Savings Bank has invested 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Deutsche Retail Bank Ag accumulated 1.45M shares or 0.05% of the stock. Tekla Cap Mgmt Limited Com holds 536,600 shares. Nokota Management Limited Partnership holds 0.09% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) or 80,020 shares.

Analysts await Universal Forest Products, Inc. (NASDAQ:UFPI) to report earnings on February, 28. They expect $0.43 earnings per share, up 26.47% or $0.09 from last year’s $0.34 per share. UFPI’s profit will be $26.31M for 21.69 P/E if the $0.43 EPS becomes a reality. After $0.55 actual earnings per share reported by Universal Forest Products, Inc. for the previous quarter, Wall Street now forecasts -21.82% negative EPS growth.

Since September 12, 2017, it had 0 insider purchases, and 8 selling transactions for $2.26 million activity. The insider COLE MICHAEL R sold 500 shares worth $55,000. 4,100 shares were sold by COLEMAN ROBERT D, worth $456,765. Another trade for 3,299 shares valued at $122,065 was made by GREENE CHARLES SCOTT on Thursday, December 14. $88,575 worth of stock was sold by WEBSTER PATRICK M on Friday, September 15. MISSAD MATTHEW J sold $743,880 worth of stock or 20,000 shares.